Mike Stratton, director of the Wellcome Trust Sanger Institute, has been knighted in the UK. Stratton founded the Cancer Genome Project at the Sanger Institute, leading the team that discovered mutations in the BRAF gene in malignant melanoma. In 2009, his team published the first full genome sequencing of two tumors, a lung cancer and a malignant melanoma. Early in his career, he discovered the BRCA2 breast cancer susceptibility gene.
Sequenom's stockholders have re-elected its board of directors to serve until the company's next annual meeting, in 2014. The board includes Ernst-Günter Afting; Kenneth Buechler, John Fazio, Harry Hixson, Myla Lai-Goldman, Richard Lerner, Ronald Lindsay, David Pendarvis, and Charles Slacik.
Genomic Health's shareholders on June 6 re-elected the company's board of directors to continue serving until the company's 2014 annual meeting. The re-elected members include Kimberly Popovits, Felix Baker, Julian Baker, Fred Cohen, Samuel Colella, Ginger Graham, Randall Livingston, and Woodrow Myers.